NSE · AJANTPHARM · Pharmaceuticals
Ajanta Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,725 Cr with net profit ₹380 Cr — a 22.02% net margin, versus 21.19% the period before.
Shareholding
As of 2026-09-30
- Promoter63.47%
- Public6.96%
- FII7.63%
- DII21.94%
61,923 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.55× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #3 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited(this company) | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
AI analysis
AI-generated · google/gemini-2.5-flashAjanta Pharma Limited is listed on the Indian markets with a market capitalization of Rs 43340 Cr. The company reported a revenue of Rs 4742.6 Cr with a revenue growth of 10.4% and a profit margin of 19.37%. Its PE ratio is 162.48 and EPS is 90.33. The book value per share stands at Rs 362.35. Return on equity is 23.33% and return on capital employed is 29.09%. The debt-to-equity ratio is 0.04.
Positives
- +The debt-to-equity ratio is low at 0.04, indicating limited reliance on debt.
- +The company demonstrated a revenue growth of 10.4%.
- +Return on Capital Employed (ROCE) is 29.09%, indicating efficient use of capital.
- +The profit margin is 19.37%.
Negatives
- −The promoter pledged 22.53% of their shareholding.
- −Promoter pledge increased from 11.16% in July 2017 to 22.53% in June 2026.
- −The trailing PE ratio of 162.48 is significantly higher compared to its EPS of Rs 90.33.
Financial performance
Ajanta Pharma Limited recorded a revenue of Rs 4742.6 Cr, indicating a revenue growth of 10.4%. The company's profit margin for the period was 19.37%. Annual net profit for Mar 2026 was Rs 1056 Cr on revenue of Rs 5624.93 Cr. Quarterly revenue for March 2026 was Rs 1421.64 Cr, with a net profit of Rs 266.7 Cr.
Profitability & Returns
The company's profit margin is 19.37%. Return on equity (ROE) is 23.33%, and return on capital employed (ROCE) is 29.09%. The earnings per share (EPS) is Rs 90.33. The latest annual EPS reported for Mar 2026 was Rs 84.51.
Balance Sheet
Ajanta Pharma Limited maintains a low debt-to-equity ratio of 0.04, suggesting a limited reliance on debt financing. The book value per share is Rs 362.35. The company’s 52-week high was Rs 3506.9 and its 52-week low was Rs 2329.9.
Ownership & Pledges
Institutional holdings include 21.80% by DIIs and 7.68% by FIIs. The public holds 7.03% of the shares. Total institutional holding stands at 29.48%. Promoter pledged shares account for 22.53% of the promoter holdings.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.